Alcon AG - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance

More Details of Alcon AG Company

Alcon AG is a Switzerland-based eye care company. The Company research, develop, manufacture, distribute and sell a full suite of eye care products within two key businesses: Surgical and Vision Care. The Company’s Surgical business is focused on ophthalmic products for cataract surgery, vitreoretinal surgery, refractive laser surgery and glaucoma surgery. The surgical portfolio includes implantables, consumables and surgical equipment required for these procedures and supports the end-to-end needs of the ophthalmic surgeon. The Company’s Vision Care business comprises of daily disposable, reusable and color-enhancing contact lenses and a portfolio of ocular health products, including products for dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The Company operates in 60 countries and serves consumers and patients in over 140 countries.

Alcon AG Info



Ticker SymbolALC

Company nameAlcon AG

IPO dateApr 09, 2019

CEOMr. David J. Endicott

Number of employees25599

Security typeOrdinary Share

Fiscal year-endApr 09

AddressRue Louis d'Affry 6

CityFRIBOURG

Stock exchangeSIX Swiss Exchange

CountrySwitzerland

Postal code1700

Phone41589113800

Websitehttps://www.alcon.ch/

Ticker SymbolALC

IPO dateApr 09, 2019

CEOMr. David J. Endicott

Company Executives of Alcon AG



Name

Name/Position

Position

Shareholding

Change

Mr. David J. Endicott

Chief Executive Officer, Director

207.11K

-11.08%

Mr. Timothy C. (Tim) Stonesifer

Chief Financial Officer, Senior Vice President

134.23K

+38.34%

Mr. Rajkumar Narayanan

Senior Vice President, President - International

37.83K

+9.30%

Mr. Ian Bell

Chief Operating Officer, Senior Vice President

30.23K

-24.88%

Ms. Karen J. May, CPA

Independent Director

28.32K

+11.14%

Mr. Laurent Attias

Senior Vice President - Corporate Strategy, Business Development and Licensing (BD&L) and Mergers and Acquisitions (M&A)

22.62K

+15.19%

Mr. Scott Harlan Maw

Independent Director

17.26K

+14.57%

Ms. Ines Poeschel

Independent Director

12.08K

+15.09%

Ms. Lynn Dorsey Bleil

Independent Director

10.94K

+13.26%

Ms. Deborah Di Sanzo

Director

--

Name

Name/Position

Position

Shareholding

Change

Mr. David J. Endicott

Chief Executive Officer, Director

207.11K

-11.08%

Mr. Timothy C. (Tim) Stonesifer

Chief Financial Officer, Senior Vice President

134.23K

+38.34%

Mr. Rajkumar Narayanan

Senior Vice President, President - International

37.83K

+9.30%

Mr. Ian Bell

Chief Operating Officer, Senior Vice President

30.23K

-24.88%

Ms. Karen J. May, CPA

Independent Director

28.32K

+11.14%

Mr. Laurent Attias

Senior Vice President - Corporate Strategy, Business Development and Licensing (BD&L) and Mergers and Acquisitions (M&A)

22.62K

+15.19%

Revenue Breakdown

Currency: USDUpdated: Mon, Oct 6

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

By BusinessUSD

Name

Revenue

Proportion

Consumables

777.00M

30.15%

Contact lenses

692.00M

26.85%

Implantables

456.00M

17.69%

Ocular health

430.00M

16.69%

Equipment/other

222.00M

8.61%

Sales to Novartis Group

19.00M

0.74%

By RegionUSD

Name

Revenue

Proportion

International

1.42B

54.99%

United States

1.16B

45.01%

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

Consumables

777.00M

30.15%

Contact lenses

692.00M

26.85%

Implantables

456.00M

17.69%

Ocular health

430.00M

16.69%

Equipment/other

222.00M

8.61%

Sales to Novartis Group

19.00M

0.74%

Shareholding Stats

Updated: Fri, Aug 15

Shareholders

Shareholder Types

Shareholders

Proportion

BlackRock Advisors (UK) Limited

4.94%

The Vanguard Group, Inc.

4.13%

Aristotle Capital Management, LLC

2.41%

UBS Fund Management (Switzerland) AG

2.29%

Norges Bank Investment Management (NBIM)

2.27%

Other

83.96%

Shareholders

Proportion

BlackRock Advisors (UK) Limited

4.94%

The Vanguard Group, Inc.

4.13%

Aristotle Capital Management, LLC

2.41%

UBS Fund Management (Switzerland) AG

2.29%

Norges Bank Investment Management (NBIM)

2.27%

Other

83.96%

Shareholder Types

Shareholders

Proportion

Investment Advisor

32.41%

Investment Advisor/Hedge Fund

25.40%

Bank and Trust

4.41%

Sovereign Wealth Fund

2.35%

Hedge Fund

2.18%

Pension Fund

1.55%

Research Firm

1.45%

Individual Investor

0.13%

Insurance Company

0.09%

Other

30.03%

Institutional Shareholding



Updated: Wed, Oct 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q3

1606

351.83M

70.41%

-6.16M

2025Q2

1631

340.08M

68.06%

-38.93M

2025Q1

1659

342.42M

68.52%

-42.21M

2024Q4

1636

370.45M

74.13%

+31.24M

2024Q3

1624

333.39M

66.72%

-2.12M

2024Q2

1594

337.16M

67.47%

-33.61M

2024Q1

1583

337.34M

67.51%

+4.25M

2023Q4

1598

326.79M

65.39%

-10.87M

2023Q3

1582

325.37M

65.11%

-21.48M

2023Q2

1575

329.22M

65.88%

-15.79M

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

BlackRock Advisors (UK) Limited

24.68M

4.94%

--

Dec 31, 2024

The Vanguard Group, Inc.

20.64M

4.13%

+781.14K

+3.93%

Jun 30, 2025

Aristotle Capital Management, LLC

12.04M

2.41%

-191.15K

-1.56%

Jun 30, 2025

UBS Fund Management (Switzerland) AG

11.47M

2.29%

-68.71K

-0.60%

Jun 30, 2025

Norges Bank Investment Management (NBIM)

11.35M

2.27%

-1.28M

-10.12%

Jun 30, 2025

Fidelity Management & Research Company LLC

10.21M

2.04%

-4.82M

-32.06%

Jun 30, 2025

Zürcher Kantonalbank (Asset Management)

9.14M

1.83%

+628.34K

+7.38%

Jun 30, 2025

AKO Capital LLP

7.71M

1.54%

+597.84K

+8.40%

Jun 30, 2025

Harding Loevner LP

7.01M

1.4%

-117.33K

-1.65%

Jun 30, 2025

T. Rowe Price Associates, Inc.

6.98M

1.4%

+2.06M

+41.82%

Jun 30, 2025

Related ETFs



Updated: Mon, Oct 6

Name

Proportion

Franklin FTSE Switzerland ETF

2.47%

Global X Aging Population ETF

2.43%

iShares MSCI Switzerland ETF

2.3%

First Trust Indxx Medical Devices ETF

1.66%

Running Oak Efficient Growth ETF

1.64%

Global X S&P Catholic Values Developed ex-US ETF

1.04%

First Trust Switzerland Alphadex Fund

0.72%

iShares Global Healthcare ETF

0.56%

Wahed Dow Jones Islamic World ETF

0.48%

iShares ESG Advanced MSCI EAFE ETF

0.47%

Franklin FTSE Switzerland ETF

Proportion2.47%

Global X Aging Population ETF

Proportion2.43%

iShares MSCI Switzerland ETF

Proportion2.3%

First Trust Indxx Medical Devices ETF

Proportion1.66%

Running Oak Efficient Growth ETF

Proportion1.64%

Global X S&P Catholic Values Developed ex-US ETF

Proportion1.04%

First Trust Switzerland Alphadex Fund

Proportion0.72%

iShares Global Healthcare ETF

Proportion0.56%

Wahed Dow Jones Islamic World ETF

Proportion0.48%

iShares ESG Advanced MSCI EAFE ETF

Proportion0.47%

Dividend



A total of 400.00M USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

Mar 01, 2022

ALC.NB Final Cash Dividend of gross CHF 0.2 paid on May 05, 2022 going ex on Apr 29, 2022

May 04, 2022

May 05, 2022

May 03, 2022

Feb 24, 2021

ALC.NB Final Cash Dividend of gross CHF 0.1 paid on May 06, 2021 going ex on May 04, 2021

May 05, 2021

May 06, 2021

May 04, 2021

Stock Split



Date

Type

Ratio

No Data

Date

Type

Ratio

No Data